Murat Karacorlu, Hakan Ozdemir, Serra Arf Karacorlu


To evaluate the effect of intravitreal triamcinolone acetonide on serous macular detachment in eyes with diabetic cystoid macular edema (CME).


Twenty eyes of 20 patients with diabetic macular edema made up the study population. The eligibility criteria for this study included clinically detectable CME in which the presence of serous macular detachment was documented by optical coherence tomography (OCT). After intravitreal injection of 0.1 ml (4 mg) triamcinolone acetonide the visual and anatomic responses were observed.


In all eyes, after an injection of triamcinolone acetonide, CME and serous macular detachment regressed. At 3 and 6 months CME and serous macular detachment had recurred in 8 (40%) and 9 eyes (45%), respectively. Patients with recurrence were retreated. No eyes lost vision at 1 month and all eyes showed improvement. At 3 months no eyes had lost vision from baseline and 17 eyes (85%) showed improvement. At six months, again no eyes had lost vision from baseline and 16 eyes (80%) maintained improved visual acuity.


Our study shows that intravitreal triamcinolone acetonide is an effective treatment for serous macular detachment in patients with diabetic CME.

Take-home message:

Intravitreal triamcinolone effectively treat not only cystoid macular edema but also serous macular detachment.